Rakesh Parikh, VP-finance of Unichem Laboratories, in an interview on CNBC-TV18 talks about his pharma company receiving approval from the US FDA for a new drug.
Ranbaxy is in focus again as the US Foods and Drugs Administration (USFDA) has filed an opposition to US-based pharmaceutical firm Mylan Inc's preliminary injunction on the launch of Ranbaxy's cholesterol treatment drug, which is a generic version of Pfizer's Lipitor, reports CNBC-TV18's Ekta Batra quoting sources.
Aurobindo Pharma touched an intraday high of Rs 193.90 and an intraday low of Rs 188. At 15:02 hrs the share was quoting at Rs 192, up Rs 0.70, or 0.37% on the NSE.
Bhaskar Narayana, Finance Director & CFO, Natco Pharma said that he no longer sees synergies with SaveMart Pharmacy existing. The revenue being generated from SaveMart Pharmacy is USD 18 million.
In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said, "It’s going to happen at April. As soon as the approval is through we will be able to supply our API to lots of customers."
Aurobindo Pharma has received USFDA tentative approval for Famclclovir Tablets. It touched an intraday high of Rs 204.80 and an intraday low of Rs 199.35. At 12:36 hrs the share was quoting at Rs 202.55, up Rs 3.00, or 1.50%.
In an interview with CNBC-TV18, AK Jain, ED of Ipca Labs said, "We are waiting for the US FDA to inspect our SEZ Indore plant. This product will be produced there so, till the time we get the approval for the plant we will not be able to take the commercial production of this product."
Aurobindo Pharma saw a sharp cut that around mid-February when USFDA had banned one of its plans. However, it has resurrected once again. CNBC-TV18’s Ekta Batra gives an update whether the tables are turning.
Aurobindo Pharma has said its Unit VI Cephalosporin facility in AP was audited by USFDA last December. However, USFDA had imposed an import alert for detention on their Unit VI products. Udayan Mukherjee thinks a large part of the pricing on the stock happened yesterday, since the announcement by the USFDA happened after market hours.
Aurobindo Pharma has clarified on United States Food and Drug Administration (USFDA) import alert for detention of Unit VI products. The drug firm has said that its Unit VI Cephalosporin facility in Andhra Pradesh, India was audited by USFDA in December last year.
Aurobindo Pharma touched a 52-week low of Rs 168.50. At 09:17 hrs the share was quoting at Rs 171, down Rs 33.60, or 16.42% on the NSE.